Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
02 August 2022 - 1:38PM
Business Wire
Appili to present update on topical formulation
of paromomycin ATI-1801 already shown to be safe and effective
against the disfiguring disease, cutaneous leishmaniasis, in Phase
3 study
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company”
or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases and biodefense, today announced
that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav
Golan, M.D, Chief Medical Officer of Appili, will participate at
the seventh iteration of WorldLeish, from August 1 to 6 2022, and
present an update on Appili program ATI-1801.
The presentation will include an overview of, Appili’s new late-stage program ATI-1801 to
treat cutaneous leishmaniasis (“CL”), the most common form of
leishmania that affects hundreds of thousands of people around the
world annually and is characterized by the formation of lesions and
ulcers that often lead to scarring, disfigurement, and
stigmatization for those infected. CL is a serious impediment to
socioeconomic development, especially for women, and a priority for
public health authorities and non-governmental organizations around
the world.
Presentation details for Appili are as follows:
Date: August 4th , 2022 Time:
10AM COT / 11AM ET Location: Programa de Estudio y Control
de Enfermedades Tropicales of the Universidad de Antioquia,
Colombia
Appili management will also be conducting in-person meetings
throughout the conference. To request a meeting, please register
for the conference here.
About ATI-1801
Licensed from the U.S. Department of Defense through the U.S.
Army Medical Materiel Development Activity, Appili’s ATI-1801 is a
novel topical product with demonstrated safety and efficacy across
multiple Phase 2 and Phase 3 studies. As current treatments are
often invasive and require hospitalization, ATI-1801 has the
potential to significantly reduce suffering from CL by providing
patients in need with a safe and effective topical therapy that can
be used in the outpatient setting.
“ATI-1801 is a unique opportunity to build on an extensive data
set and bring an urgently needed treatment to patients around the
world” said Dr. Armand Balboni, M.D., Ph.D., Chief Executive
Officer of Appili Therapeutics. “Appili is proud to play a part in
developing a solution to this long-neglected disease, and Dr. Golan
and I are greatly looking forward to sharing our progress at
WorldLeish7.”
About WorldLeish
WorldLeish is the world’s most important academic and scientific
event on leishmaniasis, a disfiguring skin infection that affects
hundreds of thousands of people around the world annually.
In its seventh version, WorldLeish expects the participation of
1,000 researchers, health professionals, and authorities and from
all over the world who will meet to discuss and share the latest
advances in research and successful experiences around neglected
tropical diseases. As well as strengthening alliances between
companies, governments, research and technology centers around a
common interest: to be able to control, prevent and find new
treatment alternatives for leishmaniasis as a global public health
problem.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical
company that is purposefully built, portfolio-driven, and
people-focused to fulfill its mission of solving life-threatening
infections. By systematically identifying urgent infections with
unmet needs, Appili’s goal is to strategically develop a pipeline
of novel therapies to prevent deaths and improve lives. The Company
is currently advancing a diverse range of anti-infectives,
including a broad-spectrum antifungal, a vaccine candidate to
eliminate a serious biological weapon threat, a topical
antiparasitic product for the treatment of a disfiguring disease,
and two novel antibiotic programs. Led by a proven management team,
Appili is at the epicenter of the global fight against infection.
For more information, visit www.AppiliTherapeutics.com.
Forward Looking Statements
This news release contains “forward-looking statements”,
including with respect the potential for ATI-1801 as a treatment
for CL. Wherever possible, words such as “may,” “would,” “could,”
“should,” “will,” “anticipate,” “believe,” “plan,” “expect,”
“intend,” “estimate,” “potential for” and similar expressions have
been used to identify these forward-looking statements. These
forward-looking statements reflect the current expectations of the
Company’s management for future growth, results of operations,
performance and business prospects and opportunities and involve
significant known and unknown risks, uncertainties and assumptions,
including, without limitation, those listed in the annual
information form of the Company dated June 23, 2022, and the other
filings made by the Company with the Canadian securities regulatory
authorities (which may be viewed at www.sedar.com). Should one or more of these risks
or uncertainties materialize or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. The Company disclaims any intention or
obligation to revise forward-looking statements whether as a result
of new information, future developments or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220801005883/en/
Media: Danielle Raabe/APCO Worldwide T: 1-646-717-9915 E:
DRaabe@apcoworldwide.com
Investor Relations: Armand Balboni, CEO Appili
Therapeutics E: Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Apr 2023 bis Apr 2024